Predictors of Bone Mineral Density Change After the First Post-Transplant Year in Kidney and Kidney-Pancreas Recipients

被引：0
|
作者：
Mainra, R. [1 ]
Bryce, R. [2 ]
Pahwa, P. [2 ]
Elder, G. [3 ]
机构：
[1] Univ Saskatchewan, Saskatchewan Transplant Program, Saskatoon, SK, Canada
[2] Univ Saskatchewan, Saskatoon, SK, Canada
[3] Westmead Hosp, Sydney, NSW, Australia
来源：
TRANSPLANTATION | 2014年 / 98卷
关键词：
D O I：
10.1097/00007890-201407151-01771
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
B927
引用
收藏
页码：527 / 527
页数：1
相关论文
共 50 条
  • [41] LOW BONE MINERAL DENSITY PREDICTS FRACTURE IN KIDNEY TRANSPLANT RECIPIENTS
    Jorgensen, Hanne Skou
    Eide, Ivar
    Bollerslev, Jens
    Godang, Kristin
    Midtvedt, Karsten
    Reisaeter, Anna
    Johnsen, Linda
    Hartmann, Anders
    Asberg, Anders
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 293 - 293
  • [42] Improvement of bone mineral density in kidney transplant recipients: it is just denosumab?
    Barbuto, Simona
    Vetrano, Daniele
    Speciale, Serena
    Aguanno, Francesco
    Comai, Giorgia
    La Manna, Gaetano
    Cianciolo, Giuseppe
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [43] Mineral and Bone Disease in Kidney Transplant Recipients
    Ariella M. Altman
    Stuart M. Sprague
    Current Osteoporosis Reports, 2018, 16 : 703 - 711
  • [44] Mineral and Bone Disease in Kidney Transplant Recipients
    Altman, Ariella M.
    Sprague, Stuart M.
    CURRENT OSTEOPOROSIS REPORTS, 2018, 16 (06): : 703 - 711
  • [45] The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation
    Lichtenberg, Shelly
    Rahamimov, Ruth
    Green, Hefziba
    Fox, Benjamin D.
    Mor, Eytan
    Gafter, Uzi
    Chagnac, Avry
    Rozen-Zvi, Benaya
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (07) : 819 - 826
  • [46] The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation
    Shelly Lichtenberg
    Ruth Rahamimov
    Hefziba Green
    Benjamin D. Fox
    Eytan Mor
    Uzi Gafter
    Avry Chagnac
    Benaya Rozen-Zvi
    European Journal of Clinical Pharmacology, 2017, 73 : 819 - 826
  • [47] Comparative incidence and outcomes of COVID-19 in kidney or kidney-pancreas transplant recipients versus kidney or kidney-pancreas waitlisted patients: A single-center study
    Santos, Carlos A. Q.
    Rhee, Yoona
    Hollinger, Edward F.
    Olaitan, Oyedolamu K.
    Schadde, Erik
    Peev, Vasil
    Saltzberg, Samuel N.
    Hertl, Martin
    CLINICAL TRANSPLANTATION, 2021, 35 (08)
  • [48] Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients
    Bustami, RT
    Ojo, AO
    Wolfe, RA
    Merion, RM
    Bennett, WM
    McDiarmid, SV
    Leichtman, AB
    Held, PJ
    Port, FK
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (01) : 87 - 93
  • [49] Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients
    Bruce, DS
    Sollinger, HW
    Humar, A
    Sutherland, DER
    Light, JA
    Kaufman, DB
    Alloway, RR
    Lo, A
    Stratta, RJ
    TRANSPLANTATION, 2001, 72 (10) : 1637 - 1643
  • [50] Long-term outcomes in simultaneous kidney-pancreas transplant recipients
    Stratta, RJ
    Sudan, R
    Sudan, D
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1564 - 1565
12345